Company intelligence / Profile preview

Cardiokol

Ownership: Private
Development stage: Preclinical

Overview

Cardiokol has developed a proprietary voice analysis technology that enables mass tele-screening for atrial fibrillation using speech platforms such as landlines, smartphones, smart speakers, and voice assistants. The solution has been launched locally in Israel with regulatory approval and agreements with HMOs. Expansion into Europe has begun with similar regulatory clearances. The company’s first use case—detection of probable atrial fibrillation—has already identified patients at risk. Additional vocal biomarkers for other diseases are under development

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital biomarker
Industry: Digital Health Medical Devices

Partnerships

Agreements with Israeli HMOsdiscussions underway with European healthcare providersplans to partner with MedTech companies/providers/payers in the US

Beyond the preview

Go deeper on Cardiokol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiokol.

Explore the full profile